Find Vebreltinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Vebreltinib, 1440964-89-5, Plb-1001, Apl-101, Vebreltinib [usan], Cbi-3103
Molecular Formula
C20H15F3N8
Molecular Weight
424.4  g/mol
InChI Key
QHXLXUIZUCJRKV-UHFFFAOYSA-N
FDA UNII
2WZP8A9VFN

Vebreltinib
Vebreltinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
1 2D Structure

Vebreltinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
2.1.2 InChI
InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
2.1.3 InChI Key
QHXLXUIZUCJRKV-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
2.2 Other Identifiers
2.2.1 UNII
2WZP8A9VFN
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Vebreltinib

2. 1440964-89-5

3. Plb-1001

4. Apl-101

5. Vebreltinib [usan]

6. Cbi-3103

7. 2wzp8a9vfn

8. Cbt-101

9. 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine

10. 1,2,4-triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6- Fluoro-2-methyl-2h-indazol-5-yl)methyl)-

11. 6-(1-cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2h-indazol-5- Yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine

12. Unii-2wzp8a9vfn

13. Vebreltinib [inn]

14. Bozitinib (plb-1001)

15. Vebreltinib [who-dd]

16. Chembl4650443

17. Schembl15594471

18. Gtpl11677

19. Plb1001

20. Bdbm107096

21. Ex-a5644

22. S6762

23. Who 11677

24. Hy-125017

25. Cs-0088607

26. Us9695175, 44

27. A937089

28. Plb-1001;t-101; Apl-101; Cbi-3103

29. 6-(1-cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2h-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine

2.4 Create Date
2013-12-23
3 Chemical and Physical Properties
Molecular Weight 424.4 g/mol
Molecular Formula C20H15F3N8
XLogP32.1
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass424.13717700 g/mol
Monoisotopic Mass424.13717700 g/mol
Topological Polar Surface Area78.7 Ų
Heavy Atom Count31
Formal Charge0
Complexity681
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1440964-89-5 / Vebreltinib API manufacturers, exporters & distributors?

Vebreltinib manufacturers, exporters & distributors 1

51

PharmaCompass offers a list of Vebreltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vebreltinib manufacturer or Vebreltinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vebreltinib manufacturer or Vebreltinib supplier.

PharmaCompass also assists you with knowing the Vebreltinib API Price utilized in the formulation of products. Vebreltinib API Price is not always fixed or binding as the Vebreltinib Price is obtained through a variety of data sources. The Vebreltinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Vebreltinib

Synonyms

1440964-89-5, Plb-1001, Apl-101, Vebreltinib [usan], Cbi-3103, 2wzp8a9vfn

Cas Number

1440964-89-5

Unique Ingredient Identifier (UNII)

2WZP8A9VFN

About Vebreltinib

Vebreltinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Vebreltinib Manufacturers

A Vebreltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vebreltinib, including repackagers and relabelers. The FDA regulates Vebreltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vebreltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Vebreltinib Suppliers

A Vebreltinib supplier is an individual or a company that provides Vebreltinib active pharmaceutical ingredient (API) or Vebreltinib finished formulations upon request. The Vebreltinib suppliers may include Vebreltinib API manufacturers, exporters, distributors and traders.

Vebreltinib GMP

Vebreltinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vebreltinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vebreltinib GMP manufacturer or Vebreltinib GMP API supplier for your needs.

Vebreltinib CoA

A Vebreltinib CoA (Certificate of Analysis) is a formal document that attests to Vebreltinib's compliance with Vebreltinib specifications and serves as a tool for batch-level quality control.

Vebreltinib CoA mostly includes findings from lab analyses of a specific batch. For each Vebreltinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vebreltinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vebreltinib EP), Vebreltinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vebreltinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty